Charney Laurence N 4

What Happened

Laurence N. Charney, a director of TG Therapeutics (TGTX), was granted 8,325 stock-tracking units (STUs) on June 11, 2026. The award is reported as a derivative grant with an acquisition price of $0 (transaction code A).

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15.
• Instrument: 8,325 STUs (derivative award) at $0.00 per unit.
• Shares owned after transaction: Not disclosed in this filing.
• Footnote F1: Each STU is a contingent right to receive either one common share or a cash payment equal to the fair market value of one share, as determined by the company's administering committee, payable no later than 30 days after the first anniversary of the grant.
• Footnote F2: STUs vest on the first anniversary of the grant only if the reporting person remains in continuous service through the vesting date.
• Timeliness: The Form 4 was filed four days after the transaction date; this may be later than the typical 2-business-day filing requirement for insiders.

Context

This was an equity award (derivative STUs), not an open-market purchase or sale. STUs do not convey immediate common stock — they give a contingent right to future stock or cash subject to committee determination and a one-year vesting/service requirement. As a grant, it is a routine compensation action rather than a direct bullish or bearish trading signal.